Trials / Withdrawn
WithdrawnNCT01862458
Empyema Treated With tPA & DNAse
Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Children's Mercy Hospital Kansas City · Academic / Other
- Sex
- All
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to scientifically evaluate a new substrate for fibrinolysis compared to our standard tPA. The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the addition of DNAse. The primary outcome variable between the two techniques will be length of hospitalization after initiation of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | tPA alone | |
| BIOLOGICAL | tPA plus dornase |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2013-05-24
- Last updated
- 2016-01-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01862458. Inclusion in this directory is not an endorsement.